ClinicalTrials.gg
RecruitingNCT05984849Updated May 20, 2026

Playing Game to Learn About Children's Vaccine Project

An interventional study of vaccination game in HPV and Vaccine-Preventable Diseases, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged 11 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Michigan State University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
11 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Vaccine-Preventable Diseases with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaccine-Preventable Diseases · United States.

Planned enrollment
7th of 15
180 · median 133
Started
2025
the only one that year
No phase
11 of 16
1 open now
Registered
9th of 16
by date
Lead sponsor
2 of 16
Michigan State University

Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 9th registered.

Vaccine-Preventable Diseases

53 studies on the registry are indexed under Vaccine-Preventable Diseases; 12 are open to participants now.

Browse Vaccine-Preventable Diseases studies →

Open to participants now

1 of the 16 studies in Vaccine-Preventable Diseases with a site in United States is open now.

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Vaccine-Preventable Diseases studies recruiting now, 2 set no upper age limit and 6 stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 11 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaccine-Preventable Diseases with a site in United States, or all of them as a file.
02

Study summary

This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14.

Read the detailed description

The study objectives are:

Objective 1: Assess feasibility (participation rate, retention, involvement, satisfaction) of one game-based interventions targeting HPV vaccination.

Objective 2: Conduct a pilot RCT with three conditions (Arm 1: HPV game-based intervention; Arm 2: usual care). The investigators will explore patterns of pre- to post-intervention change in theoretical mediators and vaccine intent, and explore levels of vaccine intent and uptake in 90 parent-child dyads of unvaccinated youth aged 11-14.

03

Conditions studied

  • HPV
  • Vaccine-Preventable Diseases

Keywords

  • adolescent
  • game intervention
04

Who can participate

Ages eligible
11 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Child sample: (1) 11-14 years old, (2) speaks and reads English, (3) has never received any doses of the HPV vaccine, (4) is not currently enrolled in another project that involves HPV-related education, and (5) agrees and provides assent to participate in research activities.
  • Parent sample: (1) parent or legal guardian of the participating child, (2) speak and read English, (3) own a smartphone, (4) agree to receive email and text messages, (5) is not currently enrolled in another project that involves HPV-related education, and (6) agree and provide consent to participate in research activities.

Exclusion Criteria: Individuals who do not meet inclusion criteria or refuse to provide consent/assent.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HPV game group

    parent-child dyads receive HPV game intervention

    Behavioral: vaccination game

  • No intervention
    Usual care

    parent-child dyads receive usual care (no intervention)

Interventions

  • Behavioralvaccination game

    A health game to promote HPV vaccination among youth

06

What researchers measure

Primary outcomes

  1. Percentage of eligible individuals agreeing to participate

    Assessed by the % of eligible individuals agreeing to participate

    Time frame: T0 (occurs after consenting and before assigning to different study conditions)

  2. Proportion of participants who are retained through follow-up

    Assessed by the % of participants who are retained through follow-up

    Time frame: T2 (occurs two months after completion of the intervention)

  3. Percentage of participants who complete the intervention and assessments

    Assessed by the % of participants who complete the intervention and assessments

    Time frame: T2 (occurs two months after completion of the intervention)

  4. Participant satisfaction with the project

    Assessed by two Likert scale questions: (1) are you satisfied with the program? (2) Will you recommend this program to others? Responses: from (1) very dissatisfied/definitely not to (5) very satisfied/definitely yes)

    Time frame: T2 (occurs two months after completion of the intervention)

  5. Intention to vaccinate the children against HPV

    Assessed by a Likert scale question: How likely will you (parent) vaccinate your child against HPV? Responses: (0) no; (1) maybe; (2) yes

    Time frame: T0 (occurs after consenting and before assigning to different study conditions); T1 (occurs immediately post intervention);T2 (occurs two months after completion of the intervention)

Secondary outcomes

  1. Children receives the first dose of HPV vaccine

    Assessed by one binary question regarding whether or not the child has received the first dose of HPV vaccine. Responses: yes, no

    Time frame: T2 (occurs two months after completion of the intervention)

07

Study locations

1 of 1 sites recruiting
  • Community
    Chandler, Arizona 85224, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified, non-sensitive data will be deposited in Dryad no later than the date of publication.

Time frame: Start: no later than the date of publication End: remain publicly available for 3 years following publication

Access criteria: All users will have open access to the data without restriction, consistent with Dryad's open-access model. Data can be accessed directly through Dryad's website using the assigned DOI, ensuring discoverability and persistent availability. No personally identifiable or sensitive information will be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 17 interventional studies with no phase under Vaccine-Preventable Diseases, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 9, 2023
StartActual
Oct 27, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984849
Responsible party
Angela Chia-Chen Chen (Professor and Endowed Chair, Michigan State University) — Principal investigator
First posted
Aug 9, 2023
Start date
Oct 27, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 20, 2026

Study contacts

ANGELA CHEN, PhD
Contact
VaccineHealthGame@msu.edu
(517) 884-4645
Nouran Ghonaim, BS
Contact
VaccineHealthGame@msu.edu
(517) 884-4645
ANGELA C CHEN, PhD
principal investigator · Michigan State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion